Beckmann et al v. Lyman - Page 11




              Interference No. 105,099                                                           Paper 25                 
              Hannum v. Immunex Corp.                                                             Page 11                 
                     The procedural distinction lies in the fact that Best and King arise in the context                  
              of ex parte examinations rather than interference proceedings.  The observation that                        
              the Office is not equipped to test theories, while certainly true, does not extend to                       
              parties in an interference, who are obligated to provide positive proof or live with the                    
              consequences of failing to do so.13                                                                         
                     An interference is, by nature, a provisional rejection of each party's involved                      
              claims over the claims of the other party under 35 U.S.C. 102(g).  The contested                            
              rejection is the rejection of the Immunex claims over the Hannum claims.  The examiner                      
              is correct that, ex parte, a burden could shift to Immunex to show why Hannum's                             
              invention does not anticipate the Immunex claims.  In an interference, however, the                         
              burden lies with the movant, 37 C.F.R. § 1.637(a), which is Hannum, not Immunex.                            
              Hannum, the putative reference, insists that it does not anticipate or render obvious the                   
              subject matter of the Immunex claims.  The evidence of record supports Hannum's                             
              position so Hannum is under no additional burden to prove its point experimentally.                         
              Instead, the burden has shifted to Immunex to disprove Hannum's contention.                                 
              Immunex has declined to do so.  Both sides must live with the consequences of their                         
              actions and inactions.  37 C.F.R. § 1.658(c).  Neither will be able to provoke an                           
              interference with the other on this subject matter at a later date.  Hannum will not be                     
              able to rely on any proofs it may have to the Immunex isoform of flt3 ligand in an                          


                     13  This is not to say that a Best-like situation could not arise in an interference.  For instance, when
              the Board raises a question of patentability under 37 C.F.R. § 1.641, the proceeding may be in the nature of an
              ex parte exam ination, particularly whe n the unpatentability appe ars to apply to both parties  such that there is
              no genuine adversity.  This is not the case here.  There is no evidence of a settlement or any other indication
              that the parties are not dealing at arms length.                                                            





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next 

Last modified: November 3, 2007